• 1
    Patsalos PN. Phenobarbitone to gabapentin: a guide to 82 years of anti-epileptic drug pharmacokinetic interactions. Seizure 1994;3: 16370.
  • 2
    Riva R, Albani F, Contin M, et al. Pharmacokinetic interactions between antiepileptic drugs: clinical considerations. Clin Pharmacokinet 1996;31: 47093.
  • 3
    Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998;32: 55463.
  • 4
    Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine: an update. Clin Pharmacokinet 1996;31: 198214.
  • 5
    Patsalos PN, Duncan JS. Antiepileptic drugs: a review of clinically significant drug interactions. Drug Saf 1993;9: 15684.
  • 6
    Cramer JA, Mattson RH. Valproic acid: in vitro plasma protein binding and interaction with phenytoin. Ther Drug Monit 1979;1: 106.
  • 7
    Patsalos PN, Lascelles PT. Effect of sodium valproate on plasma protein binding of diphenylhydantoin. J Neurol Neurosurg Psychiatry 1977;40: 5704.
  • 8
    Perucca E, Hebdige S, Frigo GM, et al. Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects. Clin Pharmacol Ther 1980;28: 77989.
  • 9
    Yukawa E, To H, Ohdo S, et al. Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics. J Clin Pharmacol 1997;37: 11607.
  • 10
    Kondo T, Otani K, Hirano T, et al. The effects of phenytoin and carbamazepine on serum concentrations of mono-unsaturated metabolites of valproic acid. Br J Clin Pharmacol 1990;29: 119.
  • 11
    Hooper WD, Franklin ME, Glue P, et al. Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of beta-oxidation. Epilepsia 1996; 37: 917.
  • 12
    Shorvon SD, Van Rijckevorsel K. Levetiracetam, a pyrrolidone recently licensed as an antiepileptic drug. J Neurol Neurosurg Psychiatry 2002 (in press).
  • 13
    Nicolas J-M, Collart P, Gerin B, et al. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab Dispos 1999;27: 2504.
  • 14
    Shorvan SD, Löwenthal A, Janz D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000;41: 117986.
  • 15
    Ben-Menachem E, Falter U, For The European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000;41: 127683.
  • 16
    Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55: 23642.
  • 17
    Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985;150: 7685.
  • 18
    Kao YJ, Tellez J, Turner DR. Dose-dependent effect of metoclopramide on cholinesterases and suxamethonium metabolism. Br J Anaesth 1990;65: 2204.
  • 19
    Jensen FS, Skovgaard LT, Viby-Mogensen J. Identification of human plasma cholinesterase variants in 6,688 individuals using biochemical analysis. Acta Anaesthesiol Scand 1995;39: 15762.
  • 20
    Minagawa T, Kohno Y, Suwa T, et al. Species differences in hydrolysis of isocarbacyclin methyl ester (TEI-9090) by blood esterases. Biochem Pharmacol 1995;49: 13615.
  • 21
    Madhu C, Duff S, Baumgarten V, et al. Metabolic deesterification of tazarotene in human blood and rat and human liver microsomes. J Pharm Sci 1997;86: 9724.
  • 22
    Slatter J, Su P, Sams J, et al. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos 1997; 25: 115764.
  • 23
    Williams FM. Clinical significance of esterases in man. Clin Pharmacokinet 1985;10: 392403.
  • 24
    Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies: conference report. Eur J Drug Metab Pharmacokinet 1991;16: 24955.
  • 25
    Center for Drug Evaluation and Research, Drug Information Branch. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products:: general considerations. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration, 2000.
  • 26
    Chun AHC, Lamm JE, Witt GF, et al. Multiple-dose evaluation of absorption characteristics of divalproex sodium tablets, a delayed-release preparation of valproate, in healthy volunteers. Clin Drug Invest 1995;10: 407.
  • 27
    Faught E. Pharmacokinetic considerations in prescribing antiepileptic drugs. Epilepsia 2001;42: 1923.
  • 28
    Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000;85: 7785.
  • 29
    Nicolas J-M, Collart P, Gerin B, et al. Levetiracetam: in vitro metabolism assays and prediction of drug-drug interaction. In: Boobis AR, Kremers P, Pelkonen O, et al., eds. Cost B1: European cooperation in the field of scientific and technical research. European Symposium on Prediction of Drug Metabolism in Man: Progress and Problems. Liège, Belgium, 1998:193–5.
  • 30
    Yu HY, Shen YZ. Analysis of tissue distribution of valproate in guinea-pigs: evidence for its capacity-limited tissue distribution. Pharm Res 1995;12: 4215.
  • 31
    Shirkey RJ, Jellett LB, Kappatos DC, et al. Distribution of sodium valproate in normal whole blood and in blood from patients with renal or hepatic disease. Eur J Clin Pharmacol 1985;28: 44752.
  • 32
    Puche E, Garcia M, Garcia H, et al. Probable pseudocholinesterase induction by valproic acid, carbamazepine and phenytoin leading to increased serum aspirin-esterase activity in epileptics. Int J Clin Pharmacol Res 1989;9: 30911.